End-of-day quote
Other stock markets
|
||
- USD | - |
10:42pm | First trial over Zantac cancer claims set to begin in Chicago | RE |
05:18pm | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
Sales 2024 * | 59.96B 5,003B | Sales 2025 * | 62.57B 5,221B | Capitalization | 145B 12,116B |
---|---|---|---|---|---|
Net income 2024 * | 6.75B 563B | Net income 2025 * | 9.29B 775B | EV / Sales 2024 * | 3.21 x |
Net Debt 2024 * | 47.04B 3,925B | Net Debt 2025 * | 41.91B 3,497B | EV / Sales 2025 * | 2.99 x |
P/E ratio 2024 * |
18.8
x | P/E ratio 2025 * |
13.7
x | Employees | - |
Yield 2024 * |
6.61% | Yield 2025 * |
6.78% | Free-Float | 59.09% |
Latest transcript on Pfizer Inc
Managers | Title | Age | Since |
---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 01/93/01 |
David Denton
DFI | Director of Finance/CFO | 59 | 02/22/02 |
Jeff Settleman
CTO | Chief Tech/Sci/R&D Officer | - | 01/19/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 01/20/01 | |
Ronald Blaylock
BRD | Director/Board Member | 64 | 23/17/23 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 27/13/27 |
1st Jan change | Capi. | |
---|---|---|
+34.00% | 664B | |
+29.29% | 567B | |
-7.75% | 354B | |
+18.53% | 330B | |
+4.95% | 286B | |
+13.79% | 234B | |
+4.93% | 199B | |
-9.78% | 196B | |
-4.89% | 148B |